CHMP gives positive opinion for isatuximab (Sarclisa)

The CHMP have recommended market authorisation for isatuximab, in combination with pomalidomide & dexamethasone, for relapsed and refractory multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor.

Source:

European Medicines Agency